4
Orphan Designations
0 approved
0
FDA Approvals
0
Active Trials
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Immune Design Corp. is a company with 4 orphan drug designations across 2 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| follicular lymphoma | Glucopyranosyl lipid A stable emulsion | Des.TrialAppr. |
| soft tissue sarcoma | combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE)dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 generecombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
7
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
7
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio